313 related articles for article (PubMed ID: 10389761)
41. Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin.
Dai J; Allard WJ; Davis G; Yeung KK
Tumour Biol; 1998; 19 Suppl 1():100-10. PubMed ID: 9422094
[TBL] [Abstract][Full Text] [Related]
42. In vivo anti-MUC1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract][Full Text] [Related]
43. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms.
Zhang L; Vlad A; Milcarek C; Finn OJ
Cancer Immunol Immunother; 2013 Mar; 62(3):423-35. PubMed ID: 22941036
[TBL] [Abstract][Full Text] [Related]
44. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression.
Hou R; Jiang L; Liu D; Lin B; Hu Z; Gao J; Zhang D; Zhang S; Iwamori M
Int J Mol Med; 2017 Aug; 40(2):293-302. PubMed ID: 28586014
[TBL] [Abstract][Full Text] [Related]
45. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line.
Kohlgraf KG; Gawron AJ; Higashi M; Meza JL; Burdick MD; Kitajima S; Kelly DL; Caffrey TC; Hollingsworth MA
Cancer Res; 2003 Aug; 63(16):5011-20. PubMed ID: 12941828
[TBL] [Abstract][Full Text] [Related]
46. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
47. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
48. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
49. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.
Mollick JA; Hodi FS; Soiffer RJ; Nadler LM; Dranoff G
Cancer Immun; 2003 Mar; 3():3. PubMed ID: 12747745
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
Passebosc-Faure K; Li G; Lambert C; Cottier M; Gentil-Perret A; Fournel P; Pérol M; Genin C
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6862-7. PubMed ID: 16203775
[TBL] [Abstract][Full Text] [Related]
51. Characterization of monoclonal antibody 436 recognizing the Arg-Pro-Ala-Pro sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells.
Nuti M; Turchi V; Rughetti A; Viacava P; Masci AM; Castagna M; Frati L
Int J Biol Markers; 1992; 7(2):71-9. PubMed ID: 1378874
[TBL] [Abstract][Full Text] [Related]
52. DNA methylation status of the MUC1 gene coding for a breast-cancer-associated protein.
Zrihan-Licht S; Weiss M; Keydar I; Wreschner DH
Int J Cancer; 1995 Jul; 62(3):245-51. PubMed ID: 7628867
[TBL] [Abstract][Full Text] [Related]
53. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
54. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
Zvirbliene A; Samonskyte L; Gedvilaite A; Voronkova T; Ulrich R; Sasnauskas K
J Immunol Methods; 2006 Apr; 311(1-2):57-70. PubMed ID: 16516908
[TBL] [Abstract][Full Text] [Related]
55. Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies.
Xing PX; Prenzoska J; McKenzie IF
Mol Immunol; 1992 May; 29(5):641-50. PubMed ID: 1374842
[TBL] [Abstract][Full Text] [Related]
56. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
[TBL] [Abstract][Full Text] [Related]
57. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
[TBL] [Abstract][Full Text] [Related]
59. Epitope-dependent differential immunoreactivities of anti-MUC1 monoclonal antibodies in human carcinomas.
Baldus SE; Goergen D; Hanisch FG; Dienes HP
Int J Oncol; 2001 Mar; 18(3):507-12. PubMed ID: 11179479
[TBL] [Abstract][Full Text] [Related]
60. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.
Gheybi E; Amani J; Salmanian AH; Mashayekhi F; Khodi S
Tumour Biol; 2014 Nov; 35(11):11489-97. PubMed ID: 25128064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
